Latest news with #strategic investment
Associated Press
5 days ago
- Business
- Associated Press
Shanghai Healthcare M&A Fund Takes Strategic Stake in MicroPort Scientific Corporation
HONG KONG SAR - Media OutReach Newswire - 25 July 2025 – MicroPort Scientific Corporation (Stock Code: 'MicroPort') announced that Shanghai Healthcare M&A Fund ('SHMAF'), a fund managed by SIIC Capital, a subsidiary of SIIC Group, has entered into a share purchase agreement to acquire 135,335,204 shares in MicroPort held by Otsuka Medical Devices Co., Ltd. Through this transaction, SHMAF will become a strategic shareholder in MicroPort, underscoring its role as a state-backed, professionally operated platform that is creating value and empowering, stabilizing, developing, and reshaping leading biopharmaceutical companies in China. As a homegrown Chinese innovator that has grown into a global leader in high-end medical devices, MicroPort serves as an anchor company for the industry. Its stable development is critical to both China's and the global high-end medical device supply chain. This investment reflects SHMAF's capital-driven approach to providing crucial support to domestic anchor companies, ensuring their stability and support growth of their core assets. SHMAF will support MicroPort's growth momentum and high-quality sustainable development with its expansive resources. Introducing a strategic shareholder to drive growth momentum. The transaction brings in a significant strategic shareholder for MicroPort. Leveraging its state-backed resources and industrial expertise, SHMAF will support MicroPort's development needs, core business expansion, and potential strategic mergers and acquisitions to create synergies that bolster the company's ongoing innovation and scale-up its operations. Optimizing resource allocation to unlock synergistic value. MicroPort has successfully incubated and nurtured multiple listed companies and specialized, highly influential small companies, in the process establishing a unique MicroPort ecosystem. SHMAF will leverage its capital and operational integration expertise to support MicroPort in refining its development strategy, optimizing resource allocation, and unlocking synergistic value—while fully respecting market dynamics and corporate autonomy—to further strengthen its ecosystem and competitive advantages. Enhancing ecosystem to enhance anchor company value. MicroPort's product portfolio spans across ten major verticals, including cardiovascular intervention, rhythm management, orthopaedics, neurovascular intervention, and surgical robotics, making it a core player in the high-end medical device industrial chain. SHMAF's support will not only drive MicroPort's growth, it will also accelerate its consolidation of upstream and downstream companies in Shanghai, attract highly-skilled talent, and facilitate breakthroughs in critical technologies and core components—ultimately enhancing the global competitiveness of China's high-end medical device industry. This transaction marks another significant step in SHMAF's commitment to serving biopharmaceutical anchor companies. Upholding its value investment principles, SHMAF will collaborate with MicroPort's shareholders and management team to leverage the strategic support and industrial synergies its state-backed platform offers. Together, they will reinforce MicroPort's position as China's innovation engine in high-end medical devices and contribute to the advancement of the biopharmaceutical industry. Hashtag: #SIICCapital #MicroPort #SHMAF The issuer is solely responsible for the content of this announcement. About MicroPort Scientific Corporation Founded in 1998 and headquartered in Shanghai's Zhangjiang, MicroPort Scientific Corporation is a leading domestic innovative high-end medical device group. It began by breaking the import monopoly in the cardiovascular stent field, and after 26 years of innovative development, its business has expanded to areas including rhythm management, orthopaedics, cardiovascular intervention, aortic and peripheral vascular intervention, neurovascular intervention, heart valves, surgical robots, and surgical medical devices. By the end of 2024, MicroPort operated in over 20,000 hospitals across 100 countries and regions worldwide, providing more than 600 solutions for patients covering over 200 diseases. MicroPort has incubated 6 A-share and Hong Kong-listed companies, owns 9 specialized and sophisticated SMEs, 4 technology giant enterprises, and 16 national high-tech enterprises, making it an outstanding representative of Shanghai's technological innovation and industrial transformation. About SIIC Capital As the active fund management platform under SIIC Group, since its establishment, SIIC Capital has been based in Shanghai, connected with Hong Kong, and oriented towards the world, actively exploring investment opportunities in strategic emerging industries such as biomedicine and green environmental protection. Through a multi-currency, full-stage fund matrix layout, it deeply serves national strategies and the construction of biomedicine highlands.
Wall Street Journal
15-07-2025
- Business
- Wall Street Journal
A Sovereign-Wealth Fund to Keep America's Technological Edge
If the U.S. wants to win the global race for technological supremacy, the country's best tool is a sovereign-wealth fund. Washington's haphazard approach to fueling national competitiveness and strategic industries isn't cutting it in today's environment. But intelligently deploying President Trump's proposed sovereign-wealth fund could secure American leadership in such critical technologies as quantum computing, artificial intelligence and advanced microchips. China is already shaping its technological future through strategic investment. The U.S. can't afford to cede leadership in technologies that will define the coming century. Other countries have used sovereign-wealth funds to great national advantage. Norway's Government Pension Fund Global is the premier example. It sets the standard for performance and transparency, delivering consistent returns while adhering to strict ethical guidelines. The Government of Singapore Investment Corp. generates outsize influence for the small nation. Oil-rich states leverage their wealth strategically with funds such as Abu Dhabi's Mubadala investment fund, which aims to position the United Arab Emirates as a global AI hub. Critics rightly point out that an American sovereign-wealth fund must be free of political interference and focused on commercial national research and defense priorities. But other nations' examples prove this is possible. There are also concerns about forming a fund when the U.S. is running budget deficits. The benefits far outweigh the risk. America needs this fund now more than ever. Both geopolitics and innovation shape the economy. It isn't enough to hope we maintain tech leadership through our financial dominance, banking leadership, private venture capital and intermittent government interventions. American firms have to grapple with difficult market distortions thanks to Chinese state investment, which places U.S. tech companies at a disadvantage. Beijing has formed various state-backed venture funds to invest in AI, quantum research and semiconductor manufacturing. These investments foster domestic innovation and advance strategic sectors. China's National Venture Capital Guidance Fund channels tens of billions of dollars of central, provincial and private capital into key technologies, aligning investments explicitly with industrial strategy.
